About the Authors

Gargi Roy

Roles Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing

royg@medimmune.com (GR); m.bowen@miami.edu (MB)

Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Shu Zhang

Roles Methodology, Visualization

Current address: Biologics Development, Gilead Sciences, San Diego, California, United States of America

Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Lina Li

Roles Data curation, Investigation, Methodology

Affiliation Cell Culture and Fermentation Sciences, MedImmune LLC, Gaithersburg, Maryland, United States of America

Eileen Higham

Roles Project administration

Current address: Process Development, Juno Therapeutics, Seattle, Washington, United States of America

Affiliation Cell Culture and Fermentation Sciences, MedImmune LLC, Gaithersburg, Maryland, United States of America

Herren Wu

Roles Funding acquisition, Writing – review & editing

Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Marcello Marelli

Roles Writing – original draft, Writing – review & editing

Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Michael A. Bowen

Roles Conceptualization, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing

royg@medimmune.com (GR); m.bowen@miami.edu (MB)

Current address: Analytical Development, Juno Therapeutics, Seattle, Washington, United States of America

Affiliation Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Competing Interests

This study was funded by MedImmune LLC. Gargi Roy, Shu Zhang, Lina Li, Eileen Higham, Herren Wu, Marcello Marelli and Michael A Bowen were employed by MedImmune during study design, data collection and analysis and decision to publish. The cell lines used in the study express proprietary products that are currently in clinical development and so cannot be made available. This alters the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. However, the described experimental strategy has applicability for other recombinant proteins produced from CHO cells and the relevant methods are shared in detail in the article for others to use.